visualizations
Phippen, Neil, MD, FACOG
Overview
overview
- Neil Phippen, MD, FACOG, is a board-certified Gynecologic Oncologist. Dr. Phippen treats a wide variety of cancers, including ovarian and fallopian tube, cervical, vulvar and vaginal cancer. As part of his practice, he performs robotic-assisted, minimally invasive surgery, laparoscopic hysterectomy, ovarian tube removal and pelvic exenteration, among many other procedures. Dr. Phippen’s passion for serving others led him to a career in medicine. He is grateful to be a physician who can partner with his patients during their most vulnerable moments, helping them restore their quality of life and feel whole. He also is fluent in English and Spanish. Dr. Phippen earned his medical degree at the University of Colorado School of Medicine. He then completed his residency at the San Antonio Uniformed Services Health Education Consortium (SAUSHEC), followed by his fellowship at the National Capital Consortium (NCC) Walter Reed National Military Medical Center. He is board-certified by the American Board of Obstetrics and Gynecology.
Affiliation
Member of
-
Clinical Program
-
Research Department
Publications
Most Recent Publications
-
2026Serum adenosine deaminase 2 predicts chemotherapy response and survival in advanced high-grade serous ovarian carcinoma. GYNECOLOGIC ONCOLOGY.Full Text via DOI: 10.1016/j.ygyno.2026.01.190
-
2025Quantitative proteomics identifies conserved proteins and altered regulation of mucin-16 in low grade serous ovarian cancers. CLINICAL PROTEOMICS. 22.Full Text via DOI: 10.1186/s12014-025-09557-1 PMID: 41053579
-
2025Extending the Hispanic/Latinx paradox to Hispanic white versus non white with I-IV cervical carcinoma. GYNECOLOGIC ONCOLOGY.Full Text via DOI: 10.1016/j.ygyno.2025.04.160
-
2025Improvements and disparities in survival for high-grade serous ovarian cancer: A contemporary assessment of real-world patients. GYNECOLOGIC ONCOLOGY.Full Text via DOI: 10.1016/j.ygyno.2025.04.170
-
2025Quantitative proteomic analyses of the tumor microenvironment in cervical adenocarcinomas by silva pattern. GYNECOLOGIC ONCOLOGY.Full Text via DOI: 10.1016/j.ygyno.2025.04.089
-
2025Silva pattern-guided proteomics reveals coordinated tumor-stroma remodeling in cervical adenocarcinoma. GYNECOLOGIC ONCOLOGY. 202.Full Text via DOI: 10.1016/j.ygyno.2025.09.002 PMID: 41014943
-
2025A deep comparative serum proteomic analysis of uterine leiomyosarcoma and benign uterine leiomyoma. GYNECOLOGIC ONCOLOGY.Full Text via DOI: 10.1016/j.ygyno.2025.04.573
-
2025Long-Term Survival in Patients With Low-Risk Cervical Cancer After Simple, Modified, or Radical Hysterectomy. JAMA NETWORK OPEN. 8.Full Text via DOI: 10.1001/jamanetworkopen.2025.10717 PMID: 40372751
-
2024Mapping three-dimensional intratumor proteomic heterogeneity in uterine serous carcinoma by multiregion microsampling. CLINICAL PROTEOMICS. 21.Full Text via DOI: 10.1186/s12014-024-09451-2 PMID: 38254014
-
2024Cracking the code: Understanding molecular signatures in ovarian cancer subgroups undergoing primary treatment. GYNECOLOGIC ONCOLOGY. S225-S225.Full Text via DOI: 10.1016/j.ygyno.2024.07.327
-
2024Deep quantitative proteomics identifies elevated MUC16 in low-compared to high-grade serous ovarian carcinoma. GYNECOLOGIC ONCOLOGY. S220-S221.Full Text via DOI: 10.1016/j.ygyno.2024.07.319
-
2024Impact of the tumor microenvironment in splenic metastasis in high-grade serous ovarian cancer revealed by quantitative proteomics. GYNECOLOGIC ONCOLOGY. S219-S220.Full Text via DOI: 10.1016/j.ygyno.2024.07.318
-
2024Prognostic biomarker validation in high grade serous carcinoma with the ovarian tumor tissue analysis consortium and the multidisciplinary ovarian cancer outcomes group. GYNECOLOGIC ONCOLOGY. S438-S440.Full Text via DOI: 10.1016/j.ygyno.2024.07.638
-
2024Multiomic analysis of uterine leiomyomas in self-described Black and White women: molecular insights into health disparities. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY. 231:3210.0-32100000000000.0.Full Text via DOI: 10.1016/j.ajog.2024.04.051 PMID: 38723985
-
2024Comparison of the clinical and genomic profiles of endometrial cancer in Appalachian and non-Appalachian patients. JOURNAL OF CLINICAL ONCOLOGY.
-
2024Proteogenomic analysis of enriched HGSOC tumor epithelium identifies prognostic signatures and therapeutic vulnerabilities (vol 8, 68, 2024). NPJ PRECISION ONCOLOGY.Full Text via DOI: 10.1038/s41698-024-00588-9 PMID: 38710993
-
2024Disease progression, survival, and molecular disparities in Black and White patients with endometrioid endometrial carcinoma in real-world registries and GOG/NRG oncology randomized phase III clinical trials. GYNECOLOGIC ONCOLOGY. 183:103-114.Full Text via DOI: 10.1016/j.ygyno.2024.03.026 PMID: 38593674
-
2024Proteogenomic analysis of enriched HGSOC tumor epithelium identifies prognostic signatures and therapeutic vulnerabilities. NPJ PRECISION ONCOLOGY. 8.Full Text via DOI: 10.1038/s41698-024-00519-8 PMID: 38480868
-
2024ProteoMixture: A cell type deconvolution tool for bulk tissue proteomic data. ISCIENCE. 27.Full Text via DOI: 10.1016/j.isci.2024.109198 PMID: 38439970
-
2024Survival disparities in non-Hispanic Black and White cervical cancer patients vary by histology and are largely explained by modifiable factors. GYNECOLOGIC ONCOLOGY. 184:224-235.Full Text via DOI: 10.1016/j.ygyno.2024.02.005 PMID: 38340648
-
2024Racial, ethnic and country of origin disparities in aggressive endometrial cancer histologic subtypes. GYNECOLOGIC ONCOLOGY. 184:31-42.Full Text via DOI: 10.1016/j.ygyno.2024.01.009 PMID: 38277919
-
2024Abstract PR-012: Proteogenomic analysis of enriched tumor epithelium identifies prognostic signatures and an increased dependency of homologous recombination proficient cells on bmi1 in high grade serous ovarian cancer. Cancer Research. 84:PR-012-PR-012.Full Text via DOI: 10.1158/1538-7445.ovarian23-pr-012
-
2023Preoperative and pre-chemotherapy CA-125 levels in high-risk early-stage ovarian cancer - An NRG/GOG study. GYNECOLOGIC ONCOLOGY. 181:54-59.Full Text via DOI: 10.1016/j.ygyno.2023.12.009 PMID: 38134754
-
2023Disparate progress in ovarian cancer survival highlights opportunities for improved equity in cancer care. GYNECOLOGIC ONCOLOGY. S210-S211.Full Text via DOI: 10.1016/j.ygyno.2023.06.246
-
2023Metronomic dosing of ovarian cancer cells with the ATR inhibitor AZD6738 leads to loss of CDC25A expression and resistance to ATRi treatment. GYNECOLOGIC ONCOLOGY. 177:60-71.Full Text via DOI: 10.1016/j.ygyno.2023.08.004 PMID: 37639904
-
2023Does the type of adjuvant radiation matter when treating elderly high-risk endometrial cancer patients with chemotherapy and radiation?. GYNECOLOGIC ONCOLOGY. S5-S6.Full Text via DOI: 10.1016/j.ygyno.2023.05.025
-
2023Survival disparities between Non-Hispanic Blacks and Whites with cervical cancer are largely dominated by adenocarcinoma histology and explained by modifiable factors. GYNECOLOGIC ONCOLOGY. S20-S21.Full Text via DOI: 10.1016/j.ygyno.2023.05.048
-
2023Factors Associated With Survival Disparities Between Non-Hispanic Black and White Patients With Uterine Cancer. JAMA NETWORK OPEN. 6.Full Text via DOI: 10.1001/jamanetworkopen.2023.8437 PMID: 37067801
-
2022Integrated multi-omic analysis of low-grade ovarian serous carcinoma collected from short and long-term survivors. JOURNAL OF TRANSLATIONAL MEDICINE. 20.Full Text via DOI: 10.1186/s12967-022-03820-x PMID: 36528667
-
2022Do US Screening Guidelines Contribute to Higher Stage and Worse Survival in our Youngest and Oldest Cervical Cancer Patients?. GYNECOLOGIC ONCOLOGY. S14-S16.
-
2022Proteomic analysis of uterine smooth muscle tumors and rare uterine fibroid variants. GYNECOLOGIC ONCOLOGY. S77-S77.
-
2022When being insured is not enough: The effect of insurance type on survival in cervical cancer. GYNECOLOGIC ONCOLOGY. S40-S40.
-
2022Paper Conditional estimates for uterine serous cancer: Tools for survivorship counseling and planning. GYNECOLOGIC ONCOLOGY. 166:90-99.Full Text via DOI: 10.1016/j.ygyno.2022.05.013 PMID: 35624045
-
2022Mixed endometrial cancer a rare histology with the largest racial disparity in survival. GYNECOLOGIC ONCOLOGY. S9-S10.
-
2022Peptide ancestry informative markers in uterine neoplasms from women of European, African, and Asian ancestry. ISCIENCE. 25.Full Text via DOI: 10.1016/j.isci.2021.103665 PMID: 35036865
-
2021Vaginal dermoid cyst. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY. 337-338.Full Text via DOI: 10.1016/j.ajog.2021.03.010 PMID: 33713684
-
2018A randomized controlled trial to determine whether a video presentation improves informed consent for hysterectomy. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY. 219.Full Text via DOI: 10.1016/j.ajog.2018.06.016 PMID: 29959929
-
2018Opioid education for early gynecologic oncology practitioners, filling a much-needed gap.. JOURNAL OF CLINICAL ONCOLOGY. 36:131-131.Full Text via DOI: 10.1200/jco.2018.36.34_suppl.131
-
2017Race-Specific Molecular Alterations Correlate With Differential Outcomes for Black and White Endometrioid Endometrial Cancer Patients. CANCER. 123:4004-4012.Full Text via DOI: 10.1002/cncr.30813 PMID: 28654152
-
2017Are different methotrexate regimens as first line therapy for low risk gestational trophoblastic neoplasia more cost effective than the dactinomycin regimen used in GOG 0174?. GYNECOLOGIC ONCOLOGY. 144:125-129.Full Text via DOI: 10.1016/j.ygyno.2016.10.038 PMID: 27816248
-
2016NUAK1 (ARK5) Is Associated with Poor Prognosis in Ovarian Cancer. FRONTIERS IN ONCOLOGY. 6.Full Text via DOI: 10.3389/fonc.2016.00213 PMID: 27833898
-
2016Does Routine Posttreatment PET/CT Add Value to the Care of Women With Locally Advanced Cervical Cancer?. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER. 26:944-950.Full Text via DOI: 10.1097/IGC.0000000000000705 PMID: 27051057
-
2016Does Routine Posttreatment PET/CT Add Value to the Care of Women With Locally Advanced Cervical Cancer?. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER. 26:944-950.Full Text via DOI: 10.1097/igc.0000000000000705
-
2016Informed Consent for Hysterectomy. OBSTETRICS AND GYNECOLOGY. 127:55S.Full Text via DOI: 10.1097/01.aog.0000483872.57979.b8
-
2015Adnexal Incarceration in a Posterior Pelvic Peritoneal Defect Mimics Ovarian Torsion. JOURNAL OF MINIMALLY INVASIVE GYNECOLOGY. 22:1113-1115.Full Text via DOI: 10.1016/j.jmig.2015.05.017 PMID: 26044591
-
2015Elevated AKAP12 in Paclitaxel-Resistant Serous Ovarian Cancer Cells Is Prognostic and Predictive of Poor Survival in Patients. JOURNAL OF PROTEOME RESEARCH. 14:1900-1910.Full Text via DOI: 10.1021/pr5012894 PMID: 25748058
-
2015Survival advantage of marriage in uterine cancer patients contrasts poor outcome for widows: A Surveillance, Epidemiology and End Results study. GYNECOLOGIC ONCOLOGY. 136:328-335.Full Text via DOI: 10.1016/j.ygyno.2014.12.027 PMID: 25546111
-
2015Bevacizumab in recurrent, persistent, or advanced stage carcinoma of the cervix: Is it cost-effective?. GYNECOLOGIC ONCOLOGY. 136:43-47.Full Text via DOI: 10.1016/j.ygyno.2014.11.003 PMID: 25448456
-
2015Abstract 4632: Poor survival associated with NUAK1 overexpression in serous ovarian cancer may be explained by chemotherapy resistance. CANCER RESEARCH. 75:4632-4632.Full Text via DOI: 10.1158/1538-7445.am2015-4632
-
2014The impact of tumor molecular profile-directed treatment on survival in recurrent ovarian cancer.. JOURNAL OF CLINICAL ONCOLOGY. 32:5591-5591.Full Text via DOI: 10.1200/jco.2014.32.15_suppl.5591
-
2013Surgical outcomes and national comprehensive cancer network compliance in advanced ovarian cancer surgery in a low volume military treatment facility. GYNECOLOGIC ONCOLOGY. 131:158-162.Full Text via DOI: 10.1016/j.ygyno.2013.07.001 PMID: 23872110
-
2013Trends in Hospital Volume and Patterns of Referral for Women with Gynecologic Cancers Adherence to Treatment Guidelines for Ovarian Cancer as a Measure of Quality Care. OBSTETRICS AND GYNECOLOGY. 905-906.PMID: 24084554
-
2013Are supportive care-based treatment strategies preferable to standard chemotherapy in recurrent cervical cancer?. GYNECOLOGIC ONCOLOGY. 130:317-322.Full Text via DOI: 10.1016/j.ygyno.2013.05.019 PMID: 23707667
-
2013Trends in Hospital Volume and Patterns of Referral for Women with Gynecologic Cancers. OBSTETRICS AND GYNECOLOGY. 122:905-906.Full Text via DOI: 10.1097/aog.0b013e3182a79fd0
-
2012Cost effectiveness of concurrent gemcitabine and cisplatin with radiation followed by adjuvant gemcitabine and cisplatin in patients with stages IIB to IVA carcinoma of the cervix. GYNECOLOGIC ONCOLOGY. 127:267-272.Full Text via DOI: 10.1016/j.ygyno.2012.08.002 PMID: 22892361
-
2011Evaluation of the Patient-Generated Subjective Global Assessment (PG-SGA) as a predictor of febrile neutropenia in gynecologic cancer patients receiving combination chemotherapy: A pilot study. GYNECOLOGIC ONCOLOGY. 123:360-364.Full Text via DOI: 10.1016/j.ygyno.2011.07.093 PMID: 21864889
-
2011Multiple synchronous primary ovarian malignancies in a patient with a MLH-1 mutation: Impact on potential fertility preservation. GYNECOLOGIC ONCOLOGY. 637-638.Full Text via DOI: 10.1016/j.ygyno.2011.02.011 PMID: 21353691
-
2010Epithelioid trophoblastic tumor masquerading as invasive squamous cell carcinoma. GYNECOLOGIC ONCOLOGY. 117:387-388.Full Text via DOI: 10.1016/j.ygyno.2010.02.013 PMID: 20223511
-
2009Weekly Topotecan and Daily Thalidomide in Patients with Recurrent Epithelial Ovarian Cancer A Report of 2 Cases. JOURNAL OF REPRODUCTIVE MEDICINE. 54:583-586.PMID: 19947038
Background
Full Name
- Neil Phippen, MD
Education
- University of Colorado School of Medicine
Residency
- San Antonio Uniformed Services Health Education Consortium (SAUSHEC)
Fellowship
- National Capital Consortium (NCC) Walter Reed National Military Medical Center
Board Certification
- The American Board of Obstetrics and Gynecology.
Contact
primary email
- Research.Institute@AdventHealth.com